190 related articles for article (PubMed ID: 38278976)
21. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
22. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
[No Abstract] [Full Text] [Related]
23. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic KRAS
Mugarza E; van Maldegem F; Boumelha J; Moore C; Rana S; Llorian Sopena M; East P; Ambler R; Anastasiou P; Romero-Clavijo P; Valand K; Cole M; Molina-Arcas M; Downward J
Sci Adv; 2022 Jul; 8(29):eabm8780. PubMed ID: 35857848
[TBL] [Abstract][Full Text] [Related]
25. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
26. Sotorasib in
Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS
N Engl J Med; 2023 Jan; 388(1):33-43. PubMed ID: 36546651
[TBL] [Abstract][Full Text] [Related]
27. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Nadal E; Chen G; Prensner JR; Shiratsuchi H; Sam C; Zhao L; Kalemkerian GP; Brenner D; Lin J; Reddy RM; Chang AC; Capellà G; Cardenal F; Beer DG; Ramnath N
J Thorac Oncol; 2014 Oct; 9(10):1513-22. PubMed ID: 25170638
[TBL] [Abstract][Full Text] [Related]
28. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
29. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
[TBL] [Abstract][Full Text] [Related]
30. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated
Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
[TBL] [Abstract][Full Text] [Related]
31. Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.
Zhang Y; Liu L; Pei J; Ren Z; Deng Y; Yu K
Oncogene; 2024 Feb; 43(9):668-681. PubMed ID: 38191673
[TBL] [Abstract][Full Text] [Related]
32. Ganoderma microsporum immunomodulatory protein combined with KRAS
Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY
Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909
[TBL] [Abstract][Full Text] [Related]
33. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
34. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L;
Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316
[TBL] [Abstract][Full Text] [Related]
35. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.
Fedele C; Li S; Teng KW; Foster CJR; Peng D; Ran H; Mita P; Geer MJ; Hattori T; Koide A; Wang Y; Tang KH; Leinwand J; Wang W; Diskin B; Deng J; Chen T; Dolgalev I; Ozerdem U; Miller G; Koide S; Wong KK; Neel BG
J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33045063
[TBL] [Abstract][Full Text] [Related]
36. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.
Naim N; Moukheiber S; Daou S; Kourie HR
Crit Rev Oncol Hematol; 2021 Dec; 168():103524. PubMed ID: 34800654
[TBL] [Abstract][Full Text] [Related]
37. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
38. EGFR Blockade Reverts Resistance to KRAS
Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
[TBL] [Abstract][Full Text] [Related]
39. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
40. The KRAS-G12C inhibitor: activity and resistance.
Liu J; Kang R; Tang D
Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
